The company made this announcement before trading hours today, 22 March 2010.
Meanwhile, the BSE Sensex was down 34.02 points, or 0.19% to 17,544.21.
On BSE, 12,948 shares were traded in the counter as against an average daily volume of 24,677 shares in the past one quarter.
The stock hit a high of Rs 960.20 and a low of Rs 923.85 so far during the day. The stock had a lifetime high of Rs 990 on 12 March 2010 and a 52-week low of Rs 165.20 on 24 March 2009.
The mid-cap stock had underperformed the market over the past one month till 19 March 2010, gaining 2.57% as compared to the Sensex's 8.56% rise. It had also underperformed the market in the past one quarter, rising 4.91% as compared to the Sensex's return of 5.13%.
The company's equity capital is Rs 27.86 crore. Face value per share is Rs 5.
The current price of Rs 957.25 discounts the company's Q3 December 2009 annualized EPS of Rs 109.82, by a PE multiple of 8.72.
Topiramate tablet is the generic version of Janssen-Ortho Inc, Canada's Topamax tablets. The drug is used for treating partial onset seizures or primary generalized tonic-clonic seizures and falls under the central nervous system (CNS) therapeutic category.
Early this month, Aurobindo Pharma received an approval from Canada for Cefuroxime Axetil tablet, which is a generic version of GlaxoSmithKline's Ceftin tablets. The drug is used for treating patients with mild to moderate infections caused by susceptible strains of the designated microorganisms. The drug falls under the antibiotic segment.
Aurobindo Pharma's net profit jumped 264.1% to Rs 148.26 crore on 12.3% rise net sales to Rs 811.06 crore in Q3 December 2009 over Q3 December 2008.
Aurobindo, which started off as a supplier of drug raw materials to semi- regulated markets, has moved up the value chain and currently sells finished generic drugs in regulated markets.